RICHLAND, WA--(Marketwired - April 15, 2013) - IsoRay Inc. (NYSE MKT: ISR) (NYSE AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 18-20, 2013 in New Orleans, Louisiana at the Hyatt Regency.
IsoRay CEO Dwight Babcock commented, "IsoRay is pleased to once again participate at the ABS annual meeting. At this venue, thought leaders and institutions, including Drs. Ron Benoit, Sushil Beriwal and Ryan P. Smith of the University of Pittsburg Medical Center (UPMC), UMPC Video and Drs. Amit A. Shaw and Gregory A. Fortier of the York Cancer Center, will present their papers documenting their experiences and success in using our products. In all there are 5 papers being presented during the convention. All of the studies being presented at the annual meeting will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used. With the continued publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer patients."
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
Babcock says the recent expansion of IsoRay's sales force, coupled with IsoRay's ongoing presentation of its products at new venues, is resulting in increased inquiries from the medical community about IsoRay's Cesium-131 (Cs-131) seed sutured mesh for the treatment of a wide array of cancers throughout the body including brain, lung, head and neck, chest wall, prostate and gynecologic cancers. Babcock says, "Leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer and I believe Cesium-131 is that solution."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of the Gliasite delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of GliaSite® or Cesium-131 will increase or continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with Cesium-131 or the Gliasite® delivery system, successful completion of future research and development activities, our ability to receive and maintain all required regulatory approvals in the U.S. and internationally, and other risks detailed from time to time in IsoRay's reports filed with the SEC.